Loading…
Loading…
EQUITY / NYSE · XASE
MAIA Biotechnology, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.2 USD · 1.6949%
Observed: Oct 5, 2026, 8:00 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/05/2026 · 1.18 USD · Volume 531,025
251 actual observations · Latest bar: 2026-10-05 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -8,317,251 USD | -5,166,058 USD | — |
| Net income | -7,943,587 USD | -5,346,963 USD | — |
| Cash and cash equivalents | 0 USD | — | — |
| Total liabilities | 7,565,161 USD | — | — |
| Total equity | 20,675,010 USD | 3,876,684 USD | +433.32% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 0 USD | — | — | 0 USD | 0 USD | 0 USD | — | — |
| Net incomeIncome statement | -7,943,587 USD | -14,313,239 USD | -6,369,652 USD | — | -22,396,172 USD | -8,903,189 USD | -18,767,410 USD | -5,346,963 USD |
| Operating profitIncome statement | -8,317,251 USD | -15,267,180 USD | — | — | -24,269,686 USD | -9,360,926 USD | -19,952,414 USD | -5,166,058 USD |
| Total assetsBalance sheet | 28,240,171 USD | — | — | 9,704,656 USD | 9,704,656 USD | 11,782,021 USD | — | — |
| Total equityBalance sheet | 20,675,010 USD | — | 27,762,768 USD | 2,375,863 USD | 2,375,863 USD | 41,670 USD | — | 3,876,684 USD |
| Total liabilitiesBalance sheet | 7,565,161 USD | — | — | 7,328,793 USD | 7,328,793 USD | 11,740,351 USD | — | — |
| Financing cash flowCash flow statement | — | 30,987,321 USD | — | — | 17,906,547 USD | — | 13,104,175 USD | — |
| Operating cash flowCash flow statement | — | -12,061,383 USD | — | — | -18,844,598 USD | — | -11,824,127 USD | — |
| Report source | Open report ↗ Published: 08/10/2026 | Open report ↗ Published: 08/10/2026 | Open report ↗ Published: 08/10/2026 | Open report ↗ Published: 08/10/2026 | Open report ↗ Published: 03/23/2026 | Open report ↗ Published: 11/07/2025 | Open report ↗ Published: 11/07/2025 | Open report ↗ Published: 08/10/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.